Jazz Pharmaceuticals plc (JAZZ)
Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock?
Investors need to pay close attention to Jazz (JAZZ) stock based on the movements in the options market lately.
Jazz (JAZZ) Upgraded to Buy: Here's Why
Jazz (JAZZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
The mean of analysts' price targets for Jazz (JAZZ) points to a 37.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View
JAZZ reports better-than-expected third-quarter results. After initiating a strategic pipeline prioritization program, the company raises its EPS guidance for 2024 by 30 cents.
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.61 per share, beating the Zacks Consensus Estimate of $5.47 per share. This compares to earnings of $4.84 per share a year ago.
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
Jazz Pharmaceuticals plc JAZZ reported record third-quarter revenue of $1.05 billion on Wednesday afternoon, up 14% year-over-year, propelled by strong sales of key therapies like Xywav, Epidiolex and Rylaze.
Insights Into Jazz (JAZZ) Q3: Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Jazz (JAZZ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Jazz (JAZZ) Could Surge 51.8%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 51.8% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
